Skip to main content

Gannex/Ascletis Reports Positive Phase II Data for NASH Treatment

Shanghai Gannex Pharma, a subsidiary of Hangzhou 's Ascletis, reported positive topline results from the China cohort of a Phase II trial for its nonalcoholic steatohepatitis (NASH) treatment. The randomized, placebo-controlled trial tested ASC40, a novel oral, once-daily fatty acid synthase (FASN) inhibitor, developed by Sagimet Biosciences of San Mateo, CA. In 2019, Ascletis led a $25 million Series E financing of Sagimet in return for China rights to the candidate. More details.... Stock Symbol: (HK:1672) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.